壳聚糖口服DNA疫苗诱导黏膜免疫并减少小鼠幽门螺杆菌定植
研究开发了编码幽门螺杆菌脲酶B亚单位的壳聚糖纳米颗粒介导口服DNA疫苗,在模拟胃和十二指肠条件下稳定且体内转染表达有效、无细胞毒性。口服疫苗诱导黏膜IgA和全身IgG反应及IFN-γ、IL-17升高,免疫小鼠胃内幽门螺杆菌定植较对照减少150倍且脲酶活性显著抑制。
要点
- 壳聚糖-DNA纳米颗粒在模拟胃和十二指肠条件下稳定,体内转染表达有效且无细胞毒性。
- 口服疫苗诱导黏膜IgA和全身IgG反应,伴IFN-γ和IL-17产生升高。
- 免疫小鼠胃内幽门螺杆菌定植较对照减少150倍,脲酶活性显著抑制。
核心结论
- 壳聚糖口服DNA疫苗可诱导保护性黏膜和全身免疫,是预防幽门螺杆菌感染的有前景方法。
研究设计与样本
- 研究开发编码幽门螺杆菌脲酶B亚单位的壳聚糖纳米颗粒介导口服DNA疫苗,并在小鼠中评估。
主要发现
- 壳聚糖-DNA纳米颗粒在模拟胃和十二指肠条件下稳定,体内转染表达有效且无细胞毒性。
- 口服疫苗诱导强黏膜IgA和全身IgG反应,伴IFN-γ和IL-17产生升高。
- 免疫小鼠胃内幽门螺杆菌定植较对照减少150倍,脲酶活性显著抑制。
- 组织学分析显示免疫细胞浸润增强,与细菌清除相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oral vaccination offers a promising strategy for controlling Helicobacter pylori infection, particularly in the face of rising antibiotic resistance and reinfection rates. In this study, we developed a chitosan nanoparticle-mediated oral DNA vaccine encoding the urease B subunit of H. pylori. The chitosan-DNA nanoparticles exhibited stability under simulated gastric and duodenal conditions and demonstrated efficient transgene expression in vivo without cytotoxicity. Oral administration of the vaccine induced strong mucosal IgA and systemic IgG responses, accompanied by elevated IFN-γ and IL-17 production. Immunized mice exhibited a 150-fold reduction in gastric H. pylori colonization and significant inhibition of urease activity compared to controls. Histological analysis revealed enhanced immune cell infiltration associated with bacterial clearance. These findings suggest that chitosan-based oral DNA vaccination can elicit protective mucosal and systemic immunity and represents a promising approach for the prevention of H. pylori infection.
引用
- Chan YL, Chao YP, Li TL, et al. Chitosan-based Oral DNA vaccine elicits mucosal immunity and reduces Helicobacter pylori colonization in mice. Vaccine. 2025. PMID: 40930041. doi:10.1016/j.vaccine.2025.127692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。